PSI Announces Collaboration With Synta Pharmaceuticals for the GALAXY-2 Phase III Non-Small Cell Lung Cancer Trial

Published: Mar 05, 2013

ZUG, Switzerland--(BUSINESS WIRE)--PSI CRO, a full-service contract research organization, announced today that the company has been selected by Synta Pharmaceuticals to conduct their GALAXY-2 trial, a Randomized Phase III Study of Ganetespib in Combination with Docetaxel versus Docetaxel Alone in Patients with Advanced Non-Small-Cell Lung Cancer. PSI is currently initiating this 500-patient study across 15+ countries. PSI has been conducting clinical trials in oncology since 1994. Lung cancer represents one of the central oncological indications in the PSI portfolio. PSI’s commitment to thorough feasibility and “go-the-extra-mile“ project management, has secured PSI’s reputation for high quality and on-time delivery in the area of lung cancer.

Back to news